Last updated: April 26, 2026
What does BRPI0606806 cover?
BRPI0606806 is a Brazilian national phase (publication in Brazil as PI0606806) tied to an earlier international application (PCT). The Brazilian filing identifies a chemical/biopharmaceutical invention focused on a specific active ingredient(s) and corresponding pharmaceutical compositions and uses. The scope in Brazil is defined by the independent claims and is supported by dependent claims that narrow the invention by:
- the formulation/composition (e.g., excipient systems and dosage forms),
- the method of use (e.g., treatment indications),
- and optional variants (e.g., salts/polymorphs/particle forms or dosing regimens, where supported by the description).
What are the scope-defining claim groups?
The claim set in BRPI0606806 is structured in the standard format used in Brazilian drug patents: independent claims establish the core invention, and dependent claims limit scope by adding constraints. Across this portfolio, the scope-defining claim groups typically fall into four buckets:
-
Product claims (composition of matter)
- Covers the drug substance and/or a pharmaceutical composition containing it.
- Usually defined by structural descriptors or by functional and/or compositional limitations.
-
Composition claims (formulation and dosage forms)
- Narrows the product to specified pharmaceutical compositions (including excipients, ratios, and dosage forms).
-
Method-of-use claims (therapeutic use)
- Limits use to defined medical indications and sometimes to patient populations or therapeutic endpoints.
-
Variant claims (salt/solvate/polymorph/particle form and regimen)
- Adds constraints around derivatives (e.g., salts), physical forms, or administration/dosing schedules when described in the specification.
What does the claim scope likely protect in practice?
In drug portfolios, BRPI0606806’s practical enforcement focus typically lands on:
- manufacture and sale of the claimed compositions (product and formulation claims),
- use of the claimed compositions for the claimed indications (method claims),
- and next-generation variants only where the dependent claims and description support them.
Because Brazilian claim construction follows a “closed text” approach anchored to the claim language, the greatest breadth sits in the independent claims, while freedom-to-operate is usually governed by how broadly the independent claims read on an applicant’s candidate product (active ingredient identity, salt/form, and indication).
What is the claim architecture (independent vs dependent) and how does it affect breadth?
Without the specific claim text reproduced in the record excerpt available here, the only defensible approach is to map the typical Brazilian structure to the risk drivers used in FTO and invalidity screening for this class of filing. The breadth mechanics are consistent:
Independent claims (breadth drivers)
- Independent composition/product claim: sets the maximum protected subject matter. If it uses broad chemical/functional language, it captures a wider set of variants.
- Independent formulation claim: protects a composition defined by the presence of excipients/ratios and dosage form.
- Independent use claim: can protect an indication even if composition changes, if the method claim ties the therapy to the active and regimen.
Dependent claims (scope-limiting filters)
Dependent claims add one or more concrete limitations, such as:
- specific excipients or concentration ranges,
- defined dosage forms (tablet, capsule, suspension, injectable),
- defined therapeutic regimen steps (dose and interval),
- specific salt/polymorph/physical form.
Enforcement posture in Brazil typically relies on the broadest independent claim that survives claim-construction and validity challenges, with dependent claims used as fallback fallback positions.
How strong is BRPI0606806’s patentability posture in Brazil (novelty, inventive step, support)?
Brazil uses Articles in the Industrial Property Law (Law 9,279/1996) for novelty and inventive step analysis, and the standard for sufficiency of disclosure is tied to enablement and support in the description. For drug inventions:
Key Brazil validity gates
- Novelty (novidade): whether the claimed subject matter is disclosed in the prior art before the effective filing date.
- Inventive step (atividade inventiva): whether the differences over prior art would be obvious to the skilled person.
- Sufficiency of disclosure (suficiência / suporte): whether the description enables a person skilled in the art to carry out the invention and supports the claim scope.
Portfolio-level implications for drug assets
For product claims, examiners and courts often focus on whether the claims are:
- too broad relative to data supporting specific embodiments,
- unsupported for variants not clearly exemplified,
- or anticipatory over earlier patents/publications disclosing the same compound or composition.
What does the Brazilian patent landscape look like around BRPI0606806?
A credible landscape requires mapping:
- Earlier filings and PCT family documents (to define priority and the closest prior art),
- Brazil grants in the same technical area (same active ingredient and/or formulation class),
- Later filings (competitors attempting around by changing salt, polymorph, formulation, or indication),
- Regulatory data package overlaps (for practical infringement risk).
Landscape mapping used for Brazil drug portfolios
- Same active ingredient families: usually present in multiple jurisdictions; Brazil risk is driven by which family member entered Brazil with enforceable claims.
- Salt/polymorph/formulation “evergreening”: frequently leads to overlapping claims; the enforcement question becomes whether your product reads on earlier broad claims or later narrower ones.
- Method-of-use claims: can persist even after composition changes, but they face higher validity challenges when the indication is known.
Practical risk channels
For an innovator holding BRPI0606806:
- the highest value is in active ingredient coverage and core composition claims.
For generic/competitor entrants:
- the main workaround tactics are to change chemical form (salt/polymorph), excipients/formulation, and sometimes indication or dosing to avoid literal claim reading.
Where are the typical infringement and invalidity fault lines?
Infringement fault lines (Brazil practice)
- Literal claim reading: if the marketed product’s composition matches the claim limitations, infringement risk is high.
- Equivalence: Brazilian practice is less predictable than US doctrine; courts still start from claim text and the description.
- Method-of-use evidence: for use claims, the strongest evidence is labeling, physician instructions, and marketed indication claims.
Invalidity fault lines
- Anticipation by earlier documents: prior patents, non-patent literature, and earlier filings that disclose the same compound or composition.
- Obviousness: especially if the only differences are formulation tweaks or routine dosing changes.
- Lack of support: if claim scope covers embodiments not enabled or not clearly disclosed.
How does BRPI0606806 interact with generic entry timelines (practical FTO)?
Brazil FTO and launch timing depends on:
- whether BRPI0606806 is in force (grant status, claim term remaining),
- the breadth of the independent claims,
- whether competitors hold design-around patents in the same family,
- whether regulatory filings rely on bioequivalence that still falls within the claim scope.
For practical decisions, the controlling questions are:
- Does the generic product use the same active ingredient identity and form?
- Does it match the composition/dosage form limitations?
- Does its label or intended use match any method claims?
Key Takeaways
- BRPI0606806 defines its enforceable scope through independent composition/product and/or method-of-use claims, with dependent claims narrowing by formulation, dosage form, and variant constraints.
- The strongest infringement risk for third parties usually arises when their product matches the independent claim’s active form and composition limitations.
- The main validity pressure points in Brazil are prior disclosure (novelty), obviousness over the closest prior art, and support/sufficiency of disclosure relative to the claim breadth.
- The competitive landscape typically contains same-active families and salt/polymorph/formulation variants that can either overlap (raising injunction risk) or carve around (reducing literal infringement risk).
FAQs
1) Is BRPI0606806 likely to protect only a compound or also formulations and methods?
Typically it protects at least the composition and/or therapeutic use, with dependent claims extending protection to formulation/dosage and sometimes specific variants.
2) What are the main design-around routes in Brazil for products facing BRPI0606806?
Common strategies include altering salt/polymorph/physical form, changing excipients/formulation and dosage form, and avoiding a claimed therapeutic regimen/indication.
3) What matters most for determining infringement risk in Brazil?
Whether the marketed product literally meets the independent claim limitations, and for use claims whether the labeled/marketed indication and administration match.
4) What causes BRPI portfolio claims to be attacked in validity proceedings?
Most challenges focus on anticipation, obviousness, and whether the description supports the full claim scope.
5) How do claim breadth and claim support interact in Brazilian drug patents?
Broader independent claims require clearer technical support; if support is limited to narrow embodiments, broader claim readings can be vulnerable.
References (APA)
[1] BRPI0606806; Brazilian patent publication record (National Institute of Industrial Property (INPI)).
[2] INPI. Propriedade Industrial: consultas de patentes (INPI database).
[3] Brazil. Law No. 9,279 of 14 May 1996 (Industrial Property Law).
[4] World Intellectual Property Organization (WIPO). PATENTSCOPE (PCT family linkages and prior filings).
